These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 34427483

  • 1. Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis.
    Li J, Wang X, Ruan G, Zhu Z, Ding C.
    Expert Opin Investig Drugs; 2021 Sep; 30(9):923-930. PubMed ID: 34427483
    [Abstract] [Full Text] [Related]

  • 2. A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis.
    Dahlberg LE, Aydemir A, Muurahainen N, Gühring H, Fredberg Edebo H, Krarup-Jensen N, Ladel CH, Jurvelin JS.
    Clin Exp Rheumatol; 2016 Sep; 34(3):445-50. PubMed ID: 27050139
    [Abstract] [Full Text] [Related]

  • 3. Sprifermin (rhFGF18) versus vehicle induces a biphasic process of extracellular matrix remodeling in human knee OA articular cartilage ex vivo.
    Reker D, Siebuhr AS, Thudium CS, Gantzel T, Ladel C, Michaelis M, Aspberg A, Berchtold MW, Karsdal MA, Gigout A, Bay-Jensen AC.
    Sci Rep; 2020 Apr 07; 10(1):6011. PubMed ID: 32265494
    [Abstract] [Full Text] [Related]

  • 4. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.
    Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, Eckstein F.
    Arthritis Rheumatol; 2014 Jul 07; 66(7):1820-31. PubMed ID: 24740822
    [Abstract] [Full Text] [Related]

  • 5. Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial.
    Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, Reinstrup Bihlet A, Byrjalsen I, Ragnar Andersen J, Eckstein F.
    JAMA; 2019 Oct 08; 322(14):1360-1370. PubMed ID: 31593273
    [Abstract] [Full Text] [Related]

  • 6. Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin.
    Marhardt K, Muurahainen N.
    Drug Res (Stuttg); 2015 Nov 08; 65 Suppl 1():S13. PubMed ID: 26536178
    [No Abstract] [Full Text] [Related]

  • 7. Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging.
    Eckstein F, Wirth W, Guermazi A, Maschek S, Aydemir A.
    Arthritis Rheumatol; 2015 Nov 08; 67(11):2916-22. PubMed ID: 26138203
    [Abstract] [Full Text] [Related]

  • 8. Effects of Sprifermin, IGF1, IGF2, BMP7, or CNP on Bovine Chondrocytes in Monolayer and 3D Culture.
    Müller S, Lindemann S, Gigout A.
    J Orthop Res; 2020 Mar 08; 38(3):653-662. PubMed ID: 31608492
    [Abstract] [Full Text] [Related]

  • 9. Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial.
    Roemer FW, Aydemir A, Lohmander S, Crema MD, Marra MD, Muurahainen N, Felson DT, Eckstein F, Guermazi A.
    BMC Musculoskelet Disord; 2016 Jul 09; 17():267. PubMed ID: 27393009
    [Abstract] [Full Text] [Related]

  • 10. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo.
    Reker D, Kjelgaard-Petersen CF, Siebuhr AS, Michaelis M, Gigout A, Karsdal MA, Ladel C, Bay-Jensen AC.
    J Transl Med; 2017 Dec 12; 15(1):250. PubMed ID: 29233174
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics, efficacy, safety and administration of intra-articular therapies for knee osteoarthritis.
    Oo WM, Liu X, Hunter DJ.
    Expert Opin Drug Metab Toxicol; 2019 Dec 12; 15(12):1021-1032. PubMed ID: 31709838
    [Abstract] [Full Text] [Related]

  • 12. Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMRI assessment over 2 years.
    Roemer FW, Kraines J, Aydemir A, Wax S, Hochberg MC, Crema MD, Guermazi A.
    Osteoarthritis Cartilage; 2020 Sep 12; 28(9):1229-1234. PubMed ID: 32619609
    [Abstract] [Full Text] [Related]

  • 13. Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study.
    Bay-Jensen AC, Manginelli AA, Karsdal M, Luo Y, He Y, Michaelis M, Guehring H, Ladel C.
    Osteoarthritis Cartilage; 2022 Jan 12; 30(1):92-99. PubMed ID: 34737064
    [Abstract] [Full Text] [Related]

  • 14. Sprifermin: Effects on Cartilage Homeostasis and Therapeutic Prospects in Cartilage-Related Diseases.
    Song Z, Li Y, Shang C, Shang G, Kou H, Li J, Chen S, Liu H.
    Front Cell Dev Biol; 2021 Jan 12; 9():786546. PubMed ID: 34970547
    [Abstract] [Full Text] [Related]

  • 15. Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.
    Eckstein F, Hochberg MC, Guehring H, Moreau F, Ona V, Bihlet AR, Byrjalsen I, Andersen JR, Daelken B, Guenther O, Ladel C, Michaelis M, Conaghan PG.
    Ann Rheum Dis; 2021 Aug 12; 80(8):1062-1069. PubMed ID: 33962962
    [Abstract] [Full Text] [Related]

  • 16. Sprifermin (recombinant human FGF18) is internalized through clathrin- and dynamin-independent pathways and degraded in primary chondrocytes.
    Sieber S, Gigout A.
    Exp Cell Res; 2020 Oct 15; 395(2):112236. PubMed ID: 32798495
    [Abstract] [Full Text] [Related]

  • 17. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix.
    Gigout A, Guehring H, Froemel D, Meurer A, Ladel C, Reker D, Bay-Jensen AC, Karsdal MA, Lindemann S.
    Osteoarthritis Cartilage; 2017 Nov 15; 25(11):1858-1867. PubMed ID: 28823647
    [Abstract] [Full Text] [Related]

  • 18. Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug.
    Sabha M, Siaton BC, Hochberg MC.
    Expert Opin Investig Drugs; 2020 Dec 15; 29(12):1339-1346. PubMed ID: 33096010
    [Abstract] [Full Text] [Related]

  • 19. Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial.
    Eckstein F, Kraines JL, Aydemir A, Wirth W, Maschek S, Hochberg MC.
    Ann Rheum Dis; 2020 Apr 15; 79(4):525-528. PubMed ID: 32098758
    [Abstract] [Full Text] [Related]

  • 20. Recombinant human FGF18 preserves depth-dependent mechanical inhomogeneity in articular cartilage.
    Meloni GR, Farran A, Mohanraj B, Guehring H, Cocca R, Rabut E, Mauck RL, Dodge GR.
    Eur Cell Mater; 2019 Aug 08; 38():23-34. PubMed ID: 31393594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.